- Home
- KROS vs BGY Comparison
KROS vs BGY Comparison
Compare KROS & BGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KROS | BGY |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 565.0M | 527.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | KROS | BGY |
|---|---|---|
| Price | $17.46 | $5.74 |
| Analyst Decision | Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $22.20 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 208.4K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.41% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $246,718,000.00 | N/A |
| Revenue This Year | $6,657.47 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.10 | ★ N/A |
| Revenue Growth | ★ 37798.31 | N/A |
| 52 Week Low | $9.12 | $4.68 |
| 52 Week High | $72.37 | $5.66 |
Technical Indicators
Market Signals| Indicator | KROS | BGY |
|---|---|---|
| Relative Strength Index (RSI) | 62.55 | 53.30 |
| Support Level | $16.63 | $5.49 |
| Resistance Level | $17.73 | $5.65 |
| Average True Range (ATR) | 0.78 | 0.07 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 55.71 | 64.20 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About BGY Blackrock Enhanced International Dividend Trust
Blackrock Enhanced International Dividend Trust has an investment objective to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust seeks to achieve its objectives by investing in equity securities of companies engaged in the energy and natural resources business and equity derivatives with exposure to the energy and natural resources industry.